Editorial
What's new in GOLD 2017?
¿Qué hay de nuevo en la GOLD 2017?
Read
4855
Timeswas read the article
1532
Total PDF
3323
Total HTML
Share statistics
array:23 [ "pii" => "S1579212917300630" "issn" => "15792129" "doi" => "10.1016/j.arbr.2017.02.015" "estado" => "S300" "fechaPublicacion" => "2017-03-01" "aid" => "1559" "copyright" => "SEPAR" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2017;53:85-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1998 "formatos" => array:3 [ "EPUB" => 144 "HTML" => 1531 "PDF" => 323 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0300289617300364" "issn" => "03002896" "doi" => "10.1016/j.arbres.2017.02.002" "estado" => "S300" "fechaPublicacion" => "2017-03-01" "aid" => "1559" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2017;53:85-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5097 "formatos" => array:3 [ "EPUB" => 137 "HTML" => 3979 "PDF" => 981 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "¿Qué hay de nuevo en la GOLD 2017?" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "85" "paginaFinal" => "86" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "What's New in GOLD 2017?" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Patricia Sobradillo Ecenarro, Ciro Casanova Macario" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Patricia" "apellidos" => "Sobradillo Ecenarro" ] 1 => array:2 [ "nombre" => "Ciro" "apellidos" => "Casanova Macario" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1579212917300630" "doi" => "10.1016/j.arbr.2017.02.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212917300630?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289617300364?idApp=UINPBA00003Z" "url" => "/03002896/0000005300000003/v4_201705130114/S0300289617300364/v4_201705130114/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1579212917300642" "issn" => "15792129" "doi" => "10.1016/j.arbr.2017.01.016" "estado" => "S300" "fechaPublicacion" => "2017-03-01" "aid" => "1530" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2017;53:87-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1747 "formatos" => array:3 [ "EPUB" => 117 "HTML" => 1173 "PDF" => 457 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Global Initiative for Chronic Obstructive Lung Disease (GOLD)-2017: The ALAT Perspective" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "87" "paginaFinal" => "88" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Global Initiative for Chronic Obstructive Lung Disease (GOLD)-2017: la visión desde alat" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Maria Montes de Oca, Rogelio Pérez-Padilla" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Maria" "apellidos" => "Montes de Oca" ] 1 => array:2 [ "nombre" => "Rogelio" "apellidos" => "Pérez-Padilla" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0300289617300078" "doi" => "10.1016/j.arbres.2017.01.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289617300078?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212917300642?idApp=UINPBA00003Z" "url" => "/15792129/0000005300000003/v1_201703240112/S1579212917300642/v1_201703240112/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "What's new in GOLD 2017?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "85" "paginaFinal" => "86" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Patricia Sobradillo Ecenarro, Ciro Casanova Macario" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Patricia Sobradillo" "apellidos" => "Ecenarro" "email" => array:1 [ 0 => "psobradillo@separ.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Ciro Casanova" "apellidos" => "Macario" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Universitario Araba, Vitoria, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Neumología-Unidad de Investigación, Hospital Universitario N.S. de la Candelaria, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Qué hay de nuevo en la GOLD 2017?" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Every 5 years, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) publishes a major revision of their global strategy for the diagnosis, treatment and prevention of COPD. The latest revision undertaken in 2011 introduced the ABCD multidimensional evaluation. This was a more comprehensive approach to the disease that considered not only airflow limitation determined by spirometry, but also the impact of symptoms, while underlining the importance of preventing exacerbations. The recently published strategy update<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> incorporates several significant changes compared to previous editions, and focuses on a new concept of COPD.</p><p id="par0010" class="elsevierStylePara elsevierViewall">It is also interesting to see that SEPAR member, Dr Álvar Agustí, Director of the Respiratory Institute at Hospital Clinic in Barcelona, was appointed Chair of the GOLD Board of Directors in September 2016.</p><p id="par0015" class="elsevierStylePara elsevierViewall">With this article, we hope to provide a structured illustration of the most important changes that appear in the new GOLD 2017.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">1. Definition and overview: A new definition of the disease is given, underlining the importance of symptoms and the fact that alveolar involvement is not always associated with airway involvement. “Inflammatory response” has also been deleted from the definition, although it is mentioned as a pathophysiological factor. New information is included in this chapter on the pathophysiology and natural history of the disease. The description of abnormal lung development featured in previous editions has been expanded in the new revision, and the different trajectories of lung function over time, expressed as FEV<span class="elsevierStyleInf">1</span>, leading to the development of COPD, are described. Other factors discussed include exposure to inhaled toxins, host factors, such as genetic abnormalities, that predispose to development of the disease, and abnormal lung development (during gestation or childhood). The possibility that a patient may have COPD without showing accelerated decline in lung function has been accepted.</p><p id="par0025" class="elsevierStylePara elsevierViewall">2. Diagnosis and initial evaluation: The current version maintains the ABCD schematic, but spirometric assessment has been separated from symptoms evaluation. The new proposal is that ABCD groups should be derived exclusively from patient symptoms and history of exacerbations. Existing cut-off points for mMRC and CAT have been maintained, even though certain studies failed to show a close concordance between CAT≥10 and mMRC≥2 in the evaluation of the clinical impact or for predicting exacerbations, depression and mortality.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a> This approach aims to avoid the imbalance that previously arose between FEV<span class="elsevierStyleInf">1</span> and exacerbations, without straying too far from previous versions of the document and maintaining the simplicity that clinicians need in their daily practice. The recommendations state that spirometry still has an important role in diagnosis and prognosis and for some therapeutic considerations (for example, wherever a discrepancy is perceived between spirometry results and the level of symptoms), for considering alternative diagnoses, or for indicating non-pharmacologic treatment, such as interventional procedures. Finally, this new approach will probably mean that fewer patients are assigned to groups C and D. Its ability to predict mortality and other outcomes must be validated.</p><p id="par0030" class="elsevierStylePara elsevierViewall">3. Evidence supporting prevention and treatment: The various pharmacologic therapies and their combinations in the treatment of stable disease and the prevention of future exacerbations have been extensively reevaluated and updated. Sections on emphysema interventions, respiratory rehabilitation, long-term home oxygen therapy, non-invasive mechanical ventilation in stable disease, self-management, and palliative and end-of-life care have been expanded. The need for regular evaluation of inhalation techniques, which should be performed in all patients, has been added. Emphasis is given to checking inhalation techniques along with therapeutic adherence before concluding that a medication is ineffective.</p><p id="par0035" class="elsevierStylePara elsevierViewall">4. Management of stable COPD: Various recommendations for the pharmacologic and non-pharmacologic treatment of COPD are presented. The focus is on more personalized treatment, directed mainly at controlling symptoms and preventing exacerbations.</p><p id="par0040" class="elsevierStylePara elsevierViewall">As in the previous update, pharmacologic treatment follows the ABCD group schematic. In this new version, however, the approach is more dynamic, since it also includes treatment escalation and de-escalation depending on response. Thus, an initial regimen is recommended and subsequently modified, depending on persistence or improvement of symptoms or exacerbations.</p><p id="par0045" class="elsevierStylePara elsevierViewall">For the non-exacerbator groups (A and B), no major changes have been introduced with respect to the previous version. However, in view of studies performed using the GOLD 2011 classification, more importance has been given to the fact that patients in category B have a higher rate of comorbidities that may affect their symptoms and prognosis, and this must be taken into account during their evaluation.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Greater differences can be found in groups C and D, as bronchodilators are recommended for the prevention of exacerbations, either in monotherapy with anticholinergics in group C patients, or in a combination of beta2-adrenergics and anticholinergics in group D. The management of patients in group D is more complicated, and more choices are offered. Thus, the possibility of targeting treatment according to the results of a laboratory parameter is proposed (starting LABA-ICS in patients with peripheral eosinophilia). Roflumilast or azithromycin may be considered in patients receiving triple therapy who continue to present exacerbations.</p><p id="par0050" class="elsevierStylePara elsevierViewall">With regard to non-pharmacologic treatment, more structured recommendations are presented in the more comprehensible format of algorithms and tables. Much more information is offered on self-management programs, dyspnea management, energy conservation and stress management in more symptomatic patients, non-invasive ventilation (a larger body of scientific evidence is presented), palliative care, and particularly, endoscopic and surgical volume reduction in patients with homogeneous or heterogeneous emphysema and hyperinflation, and an excellent new algorithm for the management of advanced COPD is provided.</p><p id="par0055" class="elsevierStylePara elsevierViewall">5. Management of exacerbations: Exacerbations (definition, diagnosis and treatment) have been extensively reviewed. One novel aspect is the presentation of detailed criteria for hospital discharge and follow-up, and the inclusion of an integrated plan for that period that aims at reducing as far as possible the risk of readmission within 1 month following discharge.</p><p id="par0060" class="elsevierStylePara elsevierViewall">6. COPD and comorbidities: Cardiovascular disease, osteoporosis, anxiety and depression, lung cancer, infections, and metabolic syndrome and diabetes, and the prevalence of these diseases are reviewed in more detail, and management of other comorbidities in COPD patients and COPD as part of multimorbidity are discussed. Another novel aspect is the emphasis on the need to simplify treatment and minimize polypharmacy in multimorbid patients.</p><p id="par0065" class="elsevierStylePara elsevierViewall">In conclusion, this new revision of the GOLD strategy introduces significant changes in the concept of COPD, expands previously underdeveloped areas, and attempts to improve the multidimensional ABCD strategy to provide a more streamlined diagnostic and therapeutic approach. This strategy must be validated, and some questions remain unanswered due to the lack of scientific evidence and the continued use of a horizontal symptomatic axis that uses tools with unbalanced cut-off points. With its new algorithms and tables with levels of evidence that facilitate comprehension, this review represents an improvement over previous versions. The intention of this new clinical strategy is that it can be used in any clinical setting anywhere in the world. It is an attempt to shift the management of COPD towards a more personalized model, more closely adapted to patients’ needs.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Ecenarro PS, Macario CC. ¿Qué hay de nuevo en la GOLD 2017?. Arch Bronconeumol. 2017;53:85–86.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2017. Available from: <a href="http://goldcopd.org/">http://goldcopd.org</a>" ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lung-function trajectories leading to chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Lange" 1 => "B. Celli" 2 => "A. Agustí" 3 => "G. Boje Jensen" 4 => "M. Divo" 5 => "R. Faner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1411532" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2015" "volumen" => "373" "paginaInicial" => "111" "paginaFinal" => "122" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26154786" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The COPD assessment test: What do we know so far? A systematic review and meta-analysis about clinical outcomes prediction and classification of patients into gold stages" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Karloh" 1 => "A.F. Mayer" 2 => "R. Maurici" 3 => "M.M.M. Pizzichini" 4 => "P.W. Jones" 5 => "E. Pizzichini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.15-1752" "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2016" "volumen" => "149" "paginaInicial" => "413" "paginaFinal" => "425" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26513112" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differential effect of mMRC dyspnea, CAT and CCQ for symptom evaluation within the new GOLD staging and mortality in COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Casanova" 1 => "J.M. Marin" 2 => "C. Martinez-Gonzalez" 3 => "P. Lucas-Ramos" 4 => "I. de Mir-Viladrich" 5 => "B. Cosio" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00246-002-9361-x" "Revista" => array:4 [ "tituloSerie" => "Chest" "fecha" => "2015" "paginaInicial" => "01" "paginaFinal" => "34" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Agusti" 1 => "L.D. Edwards" 2 => "B. Celli" 3 => "W. MacNee" 4 => "P.M.A. Calverley" 5 => "H. Müllerova" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00195212" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2013" "volumen" => "42" "paginaInicial" => "636" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23766334" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0016510714023189" "estado" => "S300" "issn" => "00165107" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15792129/0000005300000003/v1_201703240112/S1579212917300630/v1_201703240112/en/main.assets" "Apartado" => array:4 [ "identificador" => "46447" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15792129/0000005300000003/v1_201703240112/S1579212917300630/v1_201703240112/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212917300630?idApp=UINPBA00003Z" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 7 | 4 | 11 |
| 2024 October | 64 | 14 | 78 |
| 2024 September | 55 | 13 | 68 |
| 2024 August | 74 | 38 | 112 |
| 2024 July | 53 | 18 | 71 |
| 2024 June | 61 | 27 | 88 |
| 2024 May | 60 | 34 | 94 |
| 2024 April | 44 | 25 | 69 |
| 2024 March | 39 | 24 | 63 |
| 2024 February | 34 | 16 | 50 |
| 2023 March | 18 | 6 | 24 |
| 2023 February | 45 | 22 | 67 |
| 2023 January | 30 | 42 | 72 |
| 2022 December | 41 | 28 | 69 |
| 2022 November | 42 | 23 | 65 |
| 2022 October | 39 | 32 | 71 |
| 2022 September | 30 | 24 | 54 |
| 2022 August | 37 | 32 | 69 |
| 2022 July | 35 | 39 | 74 |
| 2022 June | 30 | 32 | 62 |
| 2022 May | 42 | 34 | 76 |
| 2022 April | 29 | 24 | 53 |
| 2022 March | 38 | 38 | 76 |
| 2022 February | 39 | 27 | 66 |
| 2022 January | 40 | 39 | 79 |
| 2021 December | 39 | 48 | 87 |
| 2021 November | 37 | 40 | 77 |
| 2021 October | 44 | 44 | 88 |
| 2021 September | 38 | 40 | 78 |
| 2021 August | 33 | 23 | 56 |
| 2021 July | 27 | 26 | 53 |
| 2021 June | 41 | 33 | 74 |
| 2021 May | 61 | 38 | 99 |
| 2021 April | 91 | 77 | 168 |
| 2021 March | 44 | 21 | 65 |
| 2021 February | 30 | 28 | 58 |
| 2021 January | 23 | 7 | 30 |
| 2020 December | 22 | 13 | 35 |
| 2020 November | 26 | 22 | 48 |
| 2020 October | 31 | 13 | 44 |
| 2020 September | 18 | 8 | 26 |
| 2020 August | 17 | 13 | 30 |
| 2020 July | 34 | 15 | 49 |
| 2020 June | 16 | 6 | 22 |
| 2020 May | 26 | 10 | 36 |
| 2020 April | 29 | 11 | 40 |
| 2020 March | 26 | 11 | 37 |
| 2020 February | 34 | 14 | 48 |
| 2020 January | 35 | 12 | 47 |
| 2019 December | 37 | 14 | 51 |
| 2019 November | 33 | 14 | 47 |
| 2019 October | 23 | 11 | 34 |
| 2019 September | 24 | 3 | 27 |
| 2019 August | 25 | 9 | 34 |
| 2019 July | 39 | 11 | 50 |
| 2019 June | 29 | 6 | 35 |
| 2019 May | 48 | 9 | 57 |
| 2019 April | 56 | 31 | 87 |
| 2019 March | 50 | 11 | 61 |
| 2019 February | 59 | 9 | 68 |
| 2019 January | 46 | 13 | 59 |
| 2018 December | 52 | 16 | 68 |
| 2018 November | 74 | 21 | 95 |
| 2018 October | 122 | 26 | 148 |
| 2018 September | 46 | 9 | 55 |
| 2018 May | 25 | 0 | 25 |
| 2018 April | 94 | 6 | 100 |
| 2018 March | 77 | 5 | 82 |
| 2018 February | 60 | 4 | 64 |
| 2018 January | 127 | 7 | 134 |
| 2017 December | 82 | 5 | 87 |
| 2017 November | 56 | 6 | 62 |
| 2017 October | 35 | 7 | 42 |
| 2017 September | 36 | 7 | 43 |
| 2017 August | 41 | 11 | 52 |
| 2017 July | 42 | 15 | 57 |
| 2017 June | 35 | 16 | 51 |
| 2017 May | 1 | 1 | 2 |
| 2017 April | 0 | 1 | 1 |
| 2017 March | 1 | 0 | 1 |
Show all
